Avanafil shows benefit against ED in prostate cancer patients post-surgery

According to media information released earlier today by Vivus, Inc., the company’s selective, investigational phosphodiesterase type 5 (PDE5) inhibitor known as avanafil has shown positive results in a randomized, double-blind, multi-center, placebo-controlled Phase III clinical trial for the treatment of erectile dysfunction (ED) in patients after a radical prostatectomy.

As detailed in the company’s media release, the study (also known as REVIVE-RP or TA-303) met all primary endpoints by demonstrating improvement from baseline in erectile function as measured by the Sexual Encounter Profile (both SEP2 and SEP3) and improvements in the International Index of Erectile Function (IIEF). Detailed results of the study are to be presented on June 17, 2011 at the Cancer Survivorship and Sexual Health Symposium in Washington, DC.

Vivus expects to submit a New Drug Application (NDA) to the US Food & Drug Administration later this year to seek approval of avanafil for several indications related to the treatment of erectile dysfunction. To date, no PDE5 inhibitor has ever been approved in the USA specifically for the treatment of erectile dysfunction as a consequence of surgical treatment of prostate cancer.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: